GlassScriptPhysician profile
Kayla Kimes
NPI 1396470191
$5,179.38
in general payments reported to CMS, 2019-2025
25 companies · $168 in 2025
The $168 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $789 · 2023: $2,042 · 2024: $2,180 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,390.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $803.12 | 2022-2024 | |
| Corium, LLC | $596.99 | 2022-2024 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $484.66 | 2022-2025 | Caplyta |
| Lundbeck LLC | $410.09 | 2022-2025 | Rexulti, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $378.75 | 2022-2024 | Invega Sustenna, Spravato, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $376.69 | 2022-2024 | Rexulti, Nuedexta, Abilify Mycite |
| Tris Pharma INC | $321.35 | 2022-2024 | Dyanavel Xr |
| Alkermes, INC. | $249.40 | 2022-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $226.12 | 2022-2024 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $217.35 | 2022-2024 | Austedo Xr, Austedo |
| Vanda Pharmaceuticals INC. | $208.51 | 2022-2024 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $189.39 | 2022-2024 | Ingrezza |
| Idorsia Pharmaceuticals US INC | $139.78 | 2022-2024 | Quviviq |
| Indivior INC. | $113.81 | 2023-2024 | Perseris |
| E.R. Squibb & Sons, L.L.C. | $95.36 | 2024-2025 | Cobenfy |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $66.02 | 2022-2025 | Loreev Xr |
| Supernus Pharmaceuticals, INC. | $64.76 | 2023-2024 | Qelbree, Qelbree |
| Orexo US, INC. | $44.20 | 2022-2024 | Zubsolv |
| Ironshore Pharmaceuticals INC. | $41.02 | 2023-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $37.20 | 2023-2024 | Trintellix |
| Bausch Health US, LLC | $26.42 | 2022 | |
| Biogen, INC. | $24.04 | 2024 | Zurzuvae |
| Collegium Pharmaceutical, INC. | $23.74 | 2025 | Jornay Pm |
| Noven Therapeutics, LLC | $20.61 | 2022 | |
| Neos Therapeutics, LP | $20.00 | 2024 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayla Kimes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.